Government Expands Cancer Medicine Price Controls; Cancer Patients Expected to Save ₹2,500 Crore Annually

Key Highlights:

• Government approved a 30% cap on margins charged in the supply and sale of non-scheduled anti-cancer drugs.
• This measure is expected to save cancer patients ₹2,500 crore annually.
• The decision is projected to reduce medicine prices by up to 70%.
• The intervention extends price protection to non-scheduled cancer medicines, which were previously outside strict government-set ceiling prices.
• The National Pharmaceutical Pricing Authority (NPPA) will issue the notification after an expert committee under the Directorate General of Health Services (DGHS) finalizes the list.
• The cap covers all categories of non-scheduled anti-cancer medicines, including branded, generic, domestically produced, imported, patented, and non-patented.

Detailed Insights:

• The move aims to curb excessive profiteering and address unfair pricing practices in the market.
• NPPA analysis revealed average mark-ups of approximately 170%, reaching over 700% in some non-scheduled anti-cancer medicines.
• This builds on a 2019 government directive where NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
• The 2019 intervention led to MRP reductions of up to 91% and reported annual savings of ₹984 crore.
• The decision ensures continued availability by requiring manufacturers to maintain current production levels of these life-saving medicines.
• It addresses the heavy financial burden on patients due to rising cancer incidence and substantial out-of-pocket expenses for treatment.

Key Concepts Involved:

• Non-scheduled anti-cancer drugs: Medicines for cancer treatment not included in the National List of Essential Medicines (NLEM), hence not subject to direct price ceilings.
• Maximum Retail Price (MRP): The highest price at which a retail product can be sold to the consumer.
• Trade Margin Cap: A government-imposed limit on the profit margin that can be added by distributors and retailers in the supply chain.
• National Pharmaceutical Pricing Authority (NPPA): A government regulatory agency that controls the prices of pharmaceutical drugs in India.
• Drugs (Prices Control) Order, 2013: A legal framework that empowers the government to regulate drug prices in India.